Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilomyxoid astrocytoma treated successfully with vemurafenib.

Pediatric blood & cancer - 1 Nov 2014

Skrypek Mary, Foreman Nicholas, Guillaume Daniel, Moertel Christopher

Abstract excerpt

The BRAF V600E missense mutation is known to be present in a subset of central nervous system tumors. We report a patient with a BRAF V600E mutated pilomyxoid astrocytoma who failed multiple conventional chemotherapy regimens. Treatment with vemurafenib, a molecularly targeted therapy against the mutant BRAF V600E kinase, combined with vinblastine resulted in tumor regression. Furthermore, this patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infant

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 24821190
DOI: 10.1002/pbc.25084

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Pilomyxoid astrocytoma treated successfully with vemurafenib.PMID 24821190Read ↗

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.Semantic proximity Read ↗

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.Semantic proximity Read ↗

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.Semantic proximity Read ↗

Impact of BRAF/MEK inhibitor on BRAF V600E-mutated pilocytic astrocytoma.Semantic proximity Read ↗

Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.Semantic proximity Read ↗

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.Semantic proximity Read ↗

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.Semantic proximity Read ↗

Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.Semantic proximity Read ↗

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.Semantic proximity Read ↗

Dabrafenib desensitization after a vemurafenib-induced hypersensitivity reaction in a pediatric patient with BRAFV600E mutant pilocytic astrocytomaSemantic proximity Read ↗

Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.